These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 11026016)

  • 1. [Trastuzumab for treatment of advanced breast cancers].
    Watanabe T; Shimizu C; Katsumata N; Saijo N
    Nihon Rinsho; 2000 Apr; 58 Suppl():340-4. PubMed ID: 11026016
    [No Abstract]   [Full Text] [Related]  

  • 2. Herceptin (trastuzumab): adjuvant and neoadjuvant trials.
    Yaal-Hahoshen N; Safra T
    Isr Med Assoc J; 2006 Jun; 8(6):416-21. PubMed ID: 16833172
    [No Abstract]   [Full Text] [Related]  

  • 3. Trastuzumab faces trials, clinical and otherwise.
    Tuma RS
    J Natl Cancer Inst; 2006 Mar; 98(5):296-8. PubMed ID: 16507822
    [No Abstract]   [Full Text] [Related]  

  • 4. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
    Mallmann P
    Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
    [No Abstract]   [Full Text] [Related]  

  • 5. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
    Emens LA
    Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab/docetaxel-induced nail dystrophy.
    Alexandrescu DT; Vaillant J; Wiernik PH
    Int J Dermatol; 2006 Nov; 45(11):1334-6. PubMed ID: 17076719
    [No Abstract]   [Full Text] [Related]  

  • 7. [Breast cancer].
    Tokuda Y; Saito Y; Suzuki Y; Ohta M; Tajima T
    Nihon Rinsho; 2002 Mar; 60(3):563-9. PubMed ID: 11904974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [HER-2/neu positive breast cancer: how to prescribe adjuvant trastuzumab (Herceptin)?].
    Belkacémi Y; Gligorov J; Mauriac L; Azria D
    Bull Cancer; 2006 Oct; 93(10):991-9. PubMed ID: 17074658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer.
    Ferretti G; Felici A; Papaldo P; Carlini P; Fabi A; Cognetti F
    Oncologist; 2006 May; 11(5):533; author reply 534. PubMed ID: 16720857
    [No Abstract]   [Full Text] [Related]  

  • 10. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From the molecule to the clinic--inhibiting HER2 to treat breast cancer.
    Eisenhauer EA
    N Engl J Med; 2001 Mar; 344(11):841-2. PubMed ID: 11248162
    [No Abstract]   [Full Text] [Related]  

  • 12. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
    Rowan K
    J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
    [No Abstract]   [Full Text] [Related]  

  • 13. [Docetaxel (Taxotere) in combination with trastuzumab (Herceptin)].
    Ficorella C
    Tumori; 2001; 87(1 Suppl 2):S10-8. PubMed ID: 11357872
    [No Abstract]   [Full Text] [Related]  

  • 14. Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.
    Goel S; Chirgwin J; Francis P; Stuart-Harris R; Dewar J; Mileshkin L; Snyder R; Michael M; Koczwara B
    Breast; 2011 Apr; 20(2):101-10. PubMed ID: 21183347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2-positive advanced breast cancer.
    Robert NJ; Favret AM
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):293-302. PubMed ID: 17512450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab and breast cancer.
    Palmieri C; Powles T; Vigushin D
    N Engl J Med; 2001 Sep; 345(13):996-7. PubMed ID: 11575297
    [No Abstract]   [Full Text] [Related]  

  • 17. Herceptin: from the bench to the clinic.
    Colomer R; Shamon LA; Tsai MS; Lupu R
    Cancer Invest; 2001; 19(1):49-56. PubMed ID: 11291556
    [No Abstract]   [Full Text] [Related]  

  • 18. Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.
    Altundag K; Baptista MZ
    Breast J; 2006; 12(5):497-8. PubMed ID: 16958977
    [No Abstract]   [Full Text] [Related]  

  • 19. [Clinical implications of trastuzumab].
    Saeki T; Takashima S
    Gan To Kagaku Ryoho; 2003 Aug; 30(8):1094-9. PubMed ID: 12938263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Paclitaxel for treatment of advanced breast cancers].
    Ito Y
    Nihon Rinsho; 2000 Apr; 58 Suppl():259-64. PubMed ID: 11026004
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.